Last updated: February 20, 2026
What is the drug represented by NDC 00054-8739?
NDC 00054-8739 refers to Prolia (denosumab) injection, marketed by Amgen. It is used for osteoporosis treatment in postmenopausal women, men at risk of fractures, and certain cancer-related bone conditions. Approved by the FDA in 2010, Prolia has established itself as a leading biologic in osteoporosis management.
What is the current market size for Prolia?
The US market for Prolia reached approximately $2.3 billion in 2022, with consistent annual growth driven by rising osteoporosis prevalence, expanding indications, and increased awareness.
| Year |
Estimated US Sales (USD billions) |
| 2018 |
1.2 |
| 2019 |
1.6 |
| 2020 |
2.0 |
| 2021 |
2.2 |
| 2022 |
2.3 |
Global sales are projected to exceed $4 billion in 2023, considering market penetration in Europe, Asia, and other regions.
What are the competition dynamics?
Prolia faces competition primarily from bisphosphonates, such as:
Emerging competitors include Evenity (romosozumab), approved in 2019, with projected sales of approximately $200 million globally in 2023. While denosumab is a biologic with manufacturing complexities, its efficacy and dosing schedule bolster its market share.
What are the factors influencing market growth?
-
Growing osteoporosis prevalence
- The International Osteoporosis Foundation (IOF) estimates over 200 million affected globally.
- Aging populations increase demand for treatment.
-
Expanding indications
- Use in cancer-related bone loss (e.g., breast and prostate cancer with bone metastases).
-
Reimbursement policies
- Favorable insurance coverage in the US supports continued use.
- Price negotiations and pharmacy benefit management impact net prices.
-
Patent and biosimilar landscape
- Patent expiry dates influence future pricing.
- Biosimilars expected to enter markets post-2025, potentially reducing prices by 30-50%.
What are the pricing trends?
US Pricing Environment
- Per-dose price (list) in 2023: approximately $2,400 to $2,600.
- Annual treatment cost (assuming six doses): around $14,400 to $15,600.
Price projections (next 5 years)
| Year |
Estimated Average Price (USD) per dose |
Total Annual Cost (USD) (6 doses) |
| 2023 |
$2,500 |
$15,000 |
| 2024 |
$2,400 |
$14,400 |
| 2025 |
$2,300 |
$13,800 |
| 2026 |
$2,200 |
$13,200 |
| 2027 |
$2,100 |
$12,600 |
Price reductions are expected with the advent of biosimilars, although current patents provide a buffer until 2025.
What is the outlook for market and price shifts?
- Market growth will slow as penetration saturates in major markets by 2025.
- Pricing is likely to decline gradually, influenced by biosimilar competition and payer negotiations.
- Global expansion in emerging economies could mitigate some US price declines over the long term.
- Regulatory developments in biosimilar approval could accelerate price erosion.
What strategic considerations should stakeholders factor?
- For manufacturers: Prepare for biosimilar launches; consider strategic patent extensions.
- For payers: Monitor pricing and formulary inclusion trends; evaluate biosimilar adoption.
- For investors: Market shares will adjust as biosimilars gain approval; value depends on patent protections and manufacturing capabilities.
Key Takeaways
- Prolia is a mature therapeutic asset with US sales around $2.3 billion in 2022.
- The global osteoporotic market will expand driven by aging demographics, but growth will slow due to market saturation.
- Price per dose is trending downward but remains significant, with a projected decline of approximately 10-15% over five years.
- Biosimilar entry post-2025 will influence pricing, potentially reducing net prices by up to 50% in some markets.
- Strategic responses from stakeholders will determine long-term revenue trajectory.
FAQs
Q1: When will biosimilars for Prolia enter the market?
A: Biosimilars are expected to launch around 2025, contingent upon patent expiry and regulatory approvals.
Q2: How does the pricing of Prolia compare to its competitors?
A: Prolia's per-dose cost (~$2,500) is higher than oral bisphosphonates but lower than newer biologics like romosozumab when considering annual treatment costs.
Q3: What regions offer the greatest growth potential?
A: Asia-Pacific, Latin America, and Eastern Europe show significant untapped markets due to rising osteoporosis prevalence and increasing healthcare access.
Q4: Are there significant upcoming patent protections for Prolia?
A: The primary patent expires in 2025; extensions may be pursued but biosimilar competition is imminent thereafter.
Q5: How might payer strategies impact future prices?
A: Payers are likely to negotiate deeper discounts or prefer biosimilar substitutes, further impacting list and net prices.
References
[1] Amgen Inc. (2023). Prolia Prescribing Information. Retrieved from [FDA database].
[2] International Osteoporosis Foundation. (2022). Osteoporosis Facts and Figures. https://www.iof.org
[3] IQVIA. (2023). Market Review of Bone-Active Drugs.
[4] FDA. (2020). Biosimilar Product Development and Regulation. https://www.fda.gov
